GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Follow-Up Questions
Quelle est la performance du prix de l'action GTBP ?
Le prix actuel de GTBP est de $0.8788, il a increased de 7.73% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de GT Biopharma Inc ?
GT Biopharma Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de GT Biopharma Inc ?
La capitalisation boursière actuelle de GT Biopharma Inc est de $3.1M
Est-ce que GT Biopharma Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour GT Biopharma Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte
